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  T
remendous strides have 
been made in treating HIV-
1 infection in industrialized 
countries. Combination therapy with 
antiretroviral (ARV) drugs suppresses 
virus replication, delays disease 
progression, and reduces mortality. In 
industrialized settings, plasma viral load 
assays are used in combination with 
CD4 cell counts to determine when to 
initiate therapy and when a regimen 
is failing. In addition, unlike serologic 
assays, these assays may be used to 
diagnose perinatal or acute HIV-1 
infection. 
    Unfortunately, the full beneﬁ  ts of 
antiretroviral drugs and monitoring 
tests have not yet reached the majority 
of HIV-1–infected patients who live in 
countries with limited resources. In this 
article we discuss existing data on the 
performance of alternative viral load 
assays that might be useful in resource-
limited settings. Our search strategy 
and selection criteria for relevant 
studies are shown in Box 1.
    Viral Load Assays Currently Used 
in Developed Countries
    Currently there are three HIV-1 RNA 
assays licensed by the United States 
Food and Drug Administration: Roche 
Amplicor HIV-1 Monitor Test, version 
1.5, bioMérieux NucliSens HIV-1 QT 
Assay, and Versant HIV-1 RNA 3.0 
Assay (bDNA). These assays have been 
previously described in detail ([1–7], 
Table 1) and are validated, undergo 
quality control by the manufacturers, 
recognize most HIV-1 subtypes, and are 
familiar to many clinicians. 
    However, these kits are expensive 
(kit cost of $50–$100/test in the 
US), and rely on expensive, often 
dedicated equipment that can only 
be used for that assay. Although the 
manufacturers are decreasing kit costs 
and in some instances equipment costs 
for resource-limited countries, these 
assays are still technologically complex 
and require physical resources, such 
as uninterrupted electricity, air 
conditioning, and access to clean 
water, that may not be available in 
less-developed countries (see Figure 
1) [8]. Newer assays making use of 
real-time polymerase chain reaction 
(Roche TaqMan, Abbott RealTime) 
or molecular beacon technology 
(Retina Rainbow, NucliSens EasyQ) 
are also available, but have not yet 
been approved by the Food and Drug 
Administration, and very few papers 
have been published describing their 
use.
    Barriers to Using Current Viral 
Load Assays in Resource-Limited 
Settings
    Resources vary signiﬁ  cantly by country. 
Human resources and infrastructure 
that might be readily available in major 
cities, such as trained personnel, clean 
water, and electricity, may not be 
found in more rural areas. Reference 
laboratories that have the personnel, 
equipment, and infrastructure to 
perform CD4 cell counts and viral 
load testing may lack the resources 
to purchase the kits. Thus, what 
works for one country, or even for 
one city within a country, may not 
apply in all resource-limited settings. 
Options available to developing 
countries include performing the 
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  Figure 1.   A Laboratory in Malawi 
    Many laboratories in low-income settings, 
such as the laboratory shown here, are poorly 
resourced. 
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laboratory testing at the local site or 
transporting the specimens to the 
reference laboratories for testing. A 
well-deﬁ  ned infrastructure is needed to 
ensure proper specimen handling and 
efﬁ  cient results reporting.
    While viral load kit prices have been 
decreasing for resource-poor countries, 
the cost of assay disposables and the 
establishment of a solid infrastructure 
still limit the utility of HIV-1 RNA 
for monitoring ARV therapy in most 
resource-limited settings. Inexpensive, 
technologically simpler assays are still 
needed [9–11]. Table 1 summarizes 
characteristics of some alternative 
assays, and a more detailed description, 
together with a summary of the studies 
on assay performance, is provided 
below.
    Ultrasensitive P24 Antigen Assay 
(PerkinElmer Life and Analytical 
Sciences)
    The ultrasensitive p24 (Ultra p24) 
antigen assay uses a standard ELISA 
(enzyme-linked immunosorbent assay) 
format for the capture and detection 
of HIV-1 p24 antigens coupled with 
a speciﬁ  c ampliﬁ  cation process to 
increase the assay sensitivity. Heat 
denaturation of the plasma prior 
to binding of p24 antigen in the 
ELISA step helps dissociate immune 
complexes and denature the antibodies 
so they no longer compete for binding 
to the p24 antigen. The dynamic 
range of the assay can be increased 
by using a kinetic read-out with the 
Quanti-Kin Detection System Software 
[12]. An early version of the Ultra 
p24 antigen assay was ﬁ  rst described 
by Jorg Schupbach in 1993 using the 
PerkinElmer HIV-1 p24 antigen kit 
[13]. Optimization of the standard 
p24 antigen assay by Schupbach 
[14–22] includes an external reagent 
that improves the antigen detection 
sensitivity, perhaps by greater 
dissociation of the immune complexes 
[21]. A number of investigators around 
the globe have evaluated the assay, with 
mixed results. 
    Viral Load Monitoring Using the 
Ultrasensitive P24 Antigen Assay
    Schupbach and colleagues have 
reported that the HIV-1 p24 antigen 
typically decreases in parallel with 
HIV-1 RNA in successfully treated 
patients [17] and is a good prognostic 
indicator of disease progression 
[17,20], at least among those with 
HIV-1 subtype B infection. P24 antigen 
detection is a signiﬁ  cant inverse 
correlate of CD4 cell changes in virally 
suppressed patients [21] as well as in 
patients studied longitudinally who 
were either treatment naïve (85% 
of the population) or treated with 
dual nucleoside reverse transcriptase 
inhibitors (15%) [20] or were on a 
structured treatment interruption study 
[22]. 
    Some investigators have been 
able to produce similar results 
when monitoring infected patients 
[23–26] while others have had more 
disappointing results [27–29]. Pascual 
et al. [23] compared the Roche RNA 
assay to the Ultra p24 antigen assay in 
130 patients from the US and Malawi 
(subtypes B and C) using the kit buffer. 
The RNA assay was more sensitive in 
detecting HIV-1 when compared to 
the Ultra p24 antigen assay (95.4% vs. 
84.6%). The Ultra p24 antigen assay 
detected 66.7% of specimens with viral 
loads of less than 10,000 copies/ml, 
87% of specimens with viral loads 
between 10,000 and 100,000 copies/ml, 
and 97.7% of specimens with viral load 
greater than 100,000 copies/ml. Similar 
results were observed in Burkina 
Faso [24] using the kit buffer where 
the Ultra p24 antigen assay detected 
27%, 80%, and 87% of samples with 
viral loads <1000, 1000–63,000, and 
>80,000 copies/ml, respectively. Better 
results were observed with subtype C 
clinical specimens where 95%–100% 
of samples with detectable viral loads 
over 400 copies/ml had detectable p24 
antigen levels [23,25]. 
    In South Africa, Stevens and 
colleagues [25] monitored 20 patients 
(subtype C) who were being treated 
with highly active antiretroviral 
therapy. In 19 of 20 patients the Ultra 
p24 antigen serial results (external 
buffer) paralleled the RNA results. 
Ribas and colleagues [26] evaluated 
40 patients of different HIV-1 subtypes 
being treated with ARV therapy. In 33 
patients, the changes in p24 antigen 
(external buffer) correlated well with 
RNA results, while seven others showed 
a discrepancy. Since the seven patients 
with discrepancies during monitoring 
were infected with seven different 
subtypes and other patients infected 
with the same subtypes did not show 
discrepancies, it is unlikely that the 
observed differences were related to 
virus subtype. 
    In contrast, Prado and colleagues 
[27] monitored patients in Spain 
undergoing structured treatment 
interruption and found little 
correlation between HIV-1 RNA and 
the Ultra p24 assay using the kit buffer. 
In this study, 76% of the treated 
patients and 49% of the naïve patients 
showed discordance between HIV-1 
RNA detection and p24 detection after 
viral rebound. Bonard and colleagues 
[28] tested plasma specimens from 
14 patients treated with highly active 
antiretroviral therapy in Côte d’Ivoire 
and found weaker changes during 
treatment with the Ultra p24 antigen 
assay using the kit buffer compared to 
the HIV-1 RNA results. Seven of the 
14 patients had a dramatic decrease in 
HIV-1 RNA, but only ﬁ  ve of these had 
similar, though less dramatic, changes 
in p24 antigen. Of the seven who failed 
ARV treatment, only three had p24 
antigen results that seemed to mirror 
the RNA results. Use of the external 
buffer [21] has improved the sensitivity 
of the assay 2- to 5-fold as well as the 
correlation with HIV-1 RNA (r = 0 .74 
vs. 0.61) [30]. 
    Infant Diagnosis Using the 
Ultrasensitive P24 Antigen Assay
    Diagnosis of perinatal HIV infection is 
hindered by the presence of maternal 
immunoglobulins, which can persist in 
the infant for as long as 15–18 months. 
Thus, routine antibody assays cannot be 
used to diagnose infection until after 
maternal antibodies have waned. 
  Box 1. Search Strategy and 
Selection Criteria
    Members of the Forum for 
Collaborative HIV Research Alternative 
Viral Load Assay Working Group include 
leading academic investigators in this 
ﬁ  eld as well as representatives from 
the US Centers for Disease Control and 
Prevention, the National Institutes of 
Health, charitable organizations that 
fund validation studies of the assays, 
and industrial sponsors. We included all 
peer-reviewed published papers found 
in PubMed using the search terms: 
“Alternative HIV-1 viral load assays,” 
“HIV-1 viral load AND resource-limited 
settings,” “real-time HIV-1 PCR,” “p24 
antigen,” “Cavidi,” “TaqMan,” “EasyQ,” 
“Retina Rainbow,” and “Abbott RealTime.”   
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  Table 1.   Summary of Commercially Available Viral Load Assays   
System Key Features (Cutoffs 
Reﬂ  ect Manufacturer’s 
Claims and May Not 
Be Based on the Same 
Criteria)
Parameters 
Measured
Advantages Disadvantages
Roche Molecular Systems 
(AMPLICOR Monitor 
Microwell Plate Manual and 
COBAS Automated)
Cutoff 50 copies/ml (0.5 ml); 
400 copies/ml (0.2 ml) 
HIV-1 RNA  • Equipment can be used for other diseases
• Can be used for clades A, B, C, D, E, G 
• 0.2 to 0.5 ml plasma
• High throughput
• Contamination risk
• Requires skilled technicians
• Cost
• Dedicated equipment and space
• Need good technical support
• Some reports of underestimation of non-
B subtypes
Bayer Diagnostics (VERSANT 
bDNA 3.0)
Cutoff 75 copies/ml (1.0 ml) 
in the US; Cutoff 50 copies/ml 
outside US
HIV-1 RNA • Equipment can be used for other diseases
• Can be used for clades A, B, C, D, E, G 
• High throughput
• Less contamination risk compared to PCR 
• Requires skilled technicians
• Cost
• Dedicated equipment and space
• Need good technical support
• Need 1.0 ml plasma
bioMérieux (Organon 
Teknika NucliSens QT)
Cutoff 176 copies/ml (2.0 ml); 
400 copies/ml (0.2 ml)
HIV-1 RNA • Equipment can be used for other diseases
• Can be used for clades A, B, C, D
• Can be used for all biological ﬂ  uids and dried 
blood spots (sensitivity issues with blood 
spots)
• Contamination risk 
• Requires skilled technicians
• Cost
• Dedicated equipment and space
• Need good technical support
• Need at least 1.0 ml plasma to achieve 
reported sensitivity
• Some reports of underestimation of 
certain non-B subtypes
PerkinElmer Ultrasensitive 
p24
Cutoff approximately 30,000 
copies/ml with current kit 
extraction reagent (0.05 ml); 
cutoff approximately 5,000 
copies /ml with external 
extraction reagent. Cutoff 
variable due to non-virion 
associated p24 contribution
p24 antigen • Equipment can be shared with ELISA
• Training available at CDC, UNC, Rush and 
through company
• May be used for pediatric diagnosis
• Easy training
• <1 day turn around time
• High throughput
• 0.05 ml plasma sample volume
• Dry heat block
• Needs more extensive evaluation for use 
in clinical management
• Need to understand the clinical impact of 
non-virion associate p24
• Needs more extensive evaluation in 
different subtypes
• DOS-based software for expanded 
dynamic range
Cavidi ExaVir Version 2 Cutoff approximately 500–
1000 copies/ml using version 
2.0 (1.0 ml) 
Reverse 
transcriptase 
activity
• Easy training
• Training available through company and 
at Macfarlane Burnet Institute for Medical 
Research and Public Health, Melbourne, 
Australia
• Preliminary data suggest it can be used for 
all subtypes 
• Easy to perform assay
• Potential use for clinical management
• Can be used for NNRTI drug resistance 
monitoring
• Results reported as fg RT/ml as well as RNA 
equivalent copies/ml equivalents
• Simple, inexpensive equipment
• 32° C dedicated incubator and vacuum 
pump needed
• Performance time 3 days 
• Needs more extensive evaluations for use 
in clinical management
• Needs more extensive evaluations in non-
B subtypes
• Requires 1 ml plasma, though 0.2 ml may 
be used with loss of sensitivity
• Positive and negative control not 
supplied
• Low throughput
Homebrew Real-Time PCR Cutoff varies depending on 
the system (1 copy/ml [55] to 
300 copies/ml [62]
HIV-1 RNA • Low cost reagents
• Can be extremely sensitive
• Multiplex assays possible
• Expensive equipment costs
• No manufacturer’s QA for homebrew 
reagents
Primagen Retina Rainbow/
NucliSens EasyQ
Cutoff 50 copies/ml (2.0 ml); 
500 copies/ml (0.2 ml)
HIV-1 RNA • Compatible with dried ﬂ  uid spots and 
plasma, serum, whole blood, mothers milk, 
etc.
• Equipment can be used for other bio-
markers
• Large dynamic range
• Contamination risk
• Skilled technicians
• Dedicated equipment and space
• Need good technical support
• Needs more extensive evaluation in non-
B subtypes
Abbott RealTime Cutoff ~ 40 copies/ml HIV-1 RNA • High throughput
• Large dynamic range
• Very expensive equipment
• Dedicated equipment and space
• Need good technical support
• Needs more extensive evaluation in non-
B subtypes
    CDC, Centers for Disease Control and Prevention; NNRTI, non-nucleoside reverse transcriptase inhibitor; QA, quality assurance; UNC, University of North Carolina
  DOI:  10.1371/journal.pmed.0030417.t001 
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    In industrialized countries, infants 
are typically diagnosed within days or 
weeks of birth by conﬁ  rmed, repeated 
detection of HIV-1 DNA or RNA [31–
35]. However, given the expense and 
complexity of nucleic acid testing, the 
World Health Organization strongly 
encourages the development of 
technologically simpler, less expensive 
assays that can be used to diagnose 
HIV-1 infection in early infancy [36]. 
The Ultra p24 assay is gaining support 
as a tool for detection of HIV-1 
infection in infants following mother-
to-child transmission. Lyamuya and 
colleagues [37] showed that even an 
early version of the heat-denatured 
p24 antigen assay was 99% sensitive 
and 100% speciﬁ  c in diagnosing 
HIV-1 subtypes A and D infection in 
children in Tanzania. Similar results 
have been observed with subtype B 
in Switzerland where the sensitivity 
was 100% after day 10 of age and 
speciﬁ  city was 93.8% (99.2% after 
neutralization) [38], subtype E in 
Thailand (sensitivity 100%, speciﬁ  city 
100%) [39], subtype C (sensitivity 
97%–98%, speciﬁ  city 97%–99%) 
[40,41], and multiple subtypes from 
the Democratic Republic of Congo 
using either plasma (sensitivity 92.3%, 
speciﬁ  city 100%) or dried plasma 
spots (sensitivity and speciﬁ  city 100%) 
[42]. Others have also modiﬁ  ed the 
assay for use with dried plasma spots 
[43,44], although only one has been 
successful in adapting the assay to 
dried blood spots [45]. 
    Cavidi ExaVir Load Reverse 
Transcriptase Assay
    The reverse transcriptase (RT) enzyme 
is extracted from the virus particle in 
the Cavidi RT assay using a solid phase 
extraction manifold, and is quantiﬁ  ed 
in a functional assay whereby RT 
synthesizes BrdU-DNA from a poly-A 
template bound to a 96-well plate [46]. 
Synthesized DNA is then quantiﬁ  ed 
using anti-BrdU conjugated to alkaline 
phosphatase followed by the addition 
of its substrate. The RT activity in the 
unknown sample is compared to that 
of a recombinant RT enzyme standard 
with a known concentration. The 
extrapolated result is reported as fg 
RT/ml of plasma or as HIV-1 RNA 
equivalents/ml using a conversion 
factor supplied by the manufacturer. 
The assay has recently undergone 
revisions to improve sensitivity [47]. 
Since the assay measures a virion-
associated enzyme, results are usually 
more comparable to plasma RNA 
[48]. Additionally, since this is a 
functional assay for RT and does not 
rely on speciﬁ  c protein or nucleic 
acid sequences, it performs well when 
quantifying any HIV-1 subtype [49–51]. 
A potential concern is that viruses with 
heavily mutated RT enzymes may be 
underestimated when compared to 
a recombinant wild-type RT enzyme, 
although preliminary studies suggest 
this may not be a signiﬁ  cant problem 
[49]. 
    Since this assay is newer than the 
Ultra p24 antigen assay, fewer data are 
available and most studies have been 
conducted either by or in collaboration 
with the manufacturer. Stevens and 
colleagues [25] compared the Roche 
RNA assay with both Ultra p24 antigen 
(external buffer) and the earlier 
version (version 1.0) of the Cavidi RT 
assay and found excellent correlation 
between RNA and RT results. The 
concentration of p24 antigen, RT, and 
RNA decreased in all patients after 
initiating ARV therapy, except in two 
individuals who had undetectable p24 
and RT at baseline. 
    Crowe and colleagues have tested 
both the earlier version (version 1.0) 
and the more sensitive assay (version 
2.0) in patients in Australia [49]. The 
version 1.0 RT assay had detectable 
HIV-1 RT present in 98% of samples 
(  n   = 127) with HIV-1 RNA >10,000 
copies/ml. Sensitivity using the version 
2.0 assay was higher, with detectable 
HIV RT in 95% of samples (  n   = 69) 
with HIV RNA >1,000 copies/ml. A 
positive association was found between 
the log10 HIV RNA copies/ml and log10 
HIV RT fg/ml variables using Pearson 
correlation (  r   = 0.89,   p   < 0.001;   n   = 
189 for version 1.0;   r   = 0.89;   n   = 85 for 
version 2.0). The RT activity closely 
followed the trend for HIV-1 RNA 
levels in samples (  n   = 4–10 per patient) 
from 10 HIV-1 infected patients with 
progressive disease [48]. Current (  n   = 
40), previous (  n   = 30), or no (  n   = 119) 
exposure to efavirenz had only a minor 
effect on the RT assay despite the 
tight binding of efavirenz to the HIV-
1 RT enzyme. There was a 0.20 log10 
decrease in viral load in the samples 
with efavirenz resistance mutations, as 
measured by RT when compared to 
RT polymerase chain reaction (PCR), 
indicating a possible decrease in RT 
ﬁ  tness [49]. 
    Lombart and colleagues compared 
HIV-1 RNA (Roche COBAS Amplicor 
HIV-1 Monitor Test, version 1.5) with 
Ultra p24 antigen and the Cavidi RT 
assay, version 1.0 in samples from 
Burkina Faso [24]. The RT assay 
detected 0%, 93%, and 100% of 
samples with viral loads of <10,000, 
10,000–63,000, and >80,000 copies/ml, 
respectively. Seyoum and colleagues 
[50] used the version 1.0 RT assay in 
a prospective study of 26 untreated 
patients with HIV in Ethiopia (subtype 
C), to compare results with the 
NucliSens QT assay. Although only 0.2 
ml of plasma were used in this study 
instead of the 1.0 ml speciﬁ  ed in the 
package insert, there was signiﬁ  cant 
correlation between the two assays (  n   = 
178,   r   = 0.65,   p   < 0.001), and patient RT 
activity in general mirrored HIV-1 RNA 
changes. Sivapalasingam and colleagues 
[51] compared results from the version 
2.0 RT assay with the ultrasensitive 
Roche Amplicor Monitor HIV-1 RNA 
assay version 1.5 on plasma samples 
from patients in the United States (  n   
= 29, subtype B) and Cameroon (  n   = 
21, primarily CRF02_AG). They found 
that RT levels correlated signiﬁ  cantly 
with plasma HIV-1 RNA viral loads 
using Spearman rank correlation (US: 
  r   = 0.89;   p   < 0.001; Cameroon:   r   = 0.67, 
  p   < 0.01). Among 32 samples with 
viral loads >2,000 copies/ml, 97% had 
detectable RT activity. 
  Five Key Papers on HIV Viral 
Load in Resource-Limited 
Settings 
    Majchrowicz, 2003 [10] One of the ﬁ  rst 
articles written describing the scope of 
the problem. 
    Patton et al., 2006 [45] First description 
of the successful use of dried blood spots 
with the ultrasensitive p24 antigen assay.
    Rouet et al., 2005 [62] First demonstration 
of real-time PCR technology for 
monitoring and diagnosis in a resource-
limited country.
    Schupbach et al., 1996 [15] An early 
paper comparing the ultrasensitive p24 
antigen assay with HIV RNA viral load.
    Stevens et al., 2005 [25] First independent 
comparison of the ultrasensitive p24 
antigen assay and the Cavidi reverse 
transcriptase assay in a resource-limited 
country.  
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  Real-Time  PCR/Molecular  Beacon 
Assays
    Real-time PCR such as TaqMan and 
Abbott RealTime, or molecular 
beacon assays such as Retina Rainbow 
or NucliSens EasyQ, might be useful 
for measuring viral load in resource-
limited countries [52–65]. Real-time 
PCR detects amplicon production in 
real time with each PCR cycle, and thus 
does not rely on post-ampliﬁ  cation 
detection of amplicons, which helps 
reduce the possibility of contamination 
and improves turnaround time. 
However, commercially available real-
time PCR assays are just as expensive 
as the more standard nucleic acid 
viral load tests and also use expensive 
equipment. The use of in-house 
versions of these assays can help to 
reduce kit costs, but laboratories must 
provide their own reagents such as 
primers and probes, and optimize their 
methods. In settings with multiple 
HIV-1 subtypes, care must be taken in 
selecting reagents and ampliﬁ  cation 
conditions, such as annealing 
temperatures. Quality assurance of 
each batch of such reagents remains 
problematic. 
    Although the NucliSens EasyQ 
assay has been evaluated in South 
Africa [58] and China [59], and 
the Abbott RealTime assay in Brazil 
[61], in general these assays do not 
provide a simple, less expensive 
alternative to viral load monitoring 
in resource-limited settings. Low-level 
contamination and a relatively high 
frequency of invalid results requiring 
repeat testing were some of the 
problems cited with these studies [58].
    Many of these obstacles seem to 
have been overcome in Abidjan, Côte 
d’Ivoire, where TaqMan real-time 
PCR is being routinely used for infant 
diagnosis and patient monitoring [62]. 
The limit of quantitation for this assay 
was 300 copies/ml and RNA results 
were highly correlated with both the 
Versant (  n   = 327,   r   = 0.901,   p   < 0.001) 
and the Monitor (  n   = 101,   r   = 0.856,   p   
< 0.001) HIV-1 RNA assay. The assay 
showed 100% sensitivity (  n   = 57) and 
speciﬁ  city (  n   = 210) when used in the 
early diagnosis of infants compared 
with the Versant assay. The assay also 
proved useful for monitoring the 
response to treatment in 36 children 
and 46 adults who were initiating 
antiretroviral therapy.
    Solutions to Specimen Collection 
and Transport in Rural Areas
    Viral load testing is typically performed 
on plasma, which requires a trained 
phlebotomist, access to a centrifuge, 
and a -70° C freezer for storage longer 
than a few days. Dried blood spots 
are an ideal alternative for specimen 
collection in rural areas because the 
blood is obtained either through a 
heel-stick or ﬁ  nger-stick and applied 
to ﬁ  lter paper. Once the blood has 
completely dried, it can be placed in 
its own gas impermeable ziplock bag 
along with dessicant and sent to the 
testing site at ambient temperature. 
    Dried blood spots have been used 
successfully to measure HIV-1 RNA 
in patients [66–73] and to diagnose 
perinatal HIV infection [45,73–87]. 
HIV-1 RNA in dried blood spots is 
stable for at least one year at room 
temperature [68,70] and HIV-1 DNA 
may be stable even longer [85,87], 
although proteins such as antibody 
and p24 antigen may be more labile 
[45,88]. Dried blood spots may also 
be used for HIV-1 subtyping [89] and 
genotypic resistance testing (S. Cassol, 
personal communication). A simpliﬁ  ed 
extraction method used in conjunction 
with the Roche Amplicor DNA Test 
version 1.5 [85] or real-time PCR [57], 
and their use in the Ultra p24 antigen 
assay [45], makes dried blood spots 
an attractive way to diagnose infected 
infants early and get them into clinical 
care. Further options include the use of 
a new transport medium that stabilizes 
HIV-1 RNA in plasma [90] or the use of 
mobile laboratories in rural districts.
    What Is Needed for 
Implementation of Simpliﬁ  ed 
Viral Load Testing? 
    First, each country must determine if 
the assay will quantify subtypes common 
in the region and is appropriate for 
the technical staff and laboratory 
equipment available. Infrastructure 
limitations impose signiﬁ  cant barriers 
to implementation. Infrastructure 
includes both physical resources (water, 
reliable electricity, air conditioning, 
refrigeration, other equipment) 
and human resources (trained 
technologists). Training tools, trainers, 
guidelines, and consensus protocols, as 
well as monitoring and evaluation tools, 
including proﬁ  ciency testing programs, 
all need to be established. 
    Costs must be taken into 
consideration—not only the costs of 
the kits, reagents, and supplies, but 
also the cost of equipment purchase 
(Does the assay require expensive 
equipment?), maintenance (Where is 
the nearest service technician located 
and how long does it take someone 
to repair a broken machine, and at 
what cost?), kit procurement (How 
long will it take to get kits from the 
manufacturer or distributor? Will 
lengthy delays in shipping or customs 
render the kits useless?), and the 
cost of labor (What are the hands-on 
time labor costs for the assay? Is local 
training available?). Other questions to 
consider include: Are there established 
external quality assurance programs 
available for the assay? Who will 
provide these? What will they cost? 
What approval is required by ministries 
of health? 
    Once the assay is deemed acceptable, 
clinical validation studies in relevant 
populations are required to prove 
comparability to the gold standard 
with respect to sensitivity, speciﬁ  city, 
precision, reproducibility, dynamic 
range, and linearity. It is imperative 
that the laboratory performing the 
gold standard assay is participating 
in national or international quality 
assurance programs in order for the 
comparisons to be meaningful.
    Lastly, there must be acceptance 
and understanding by the clinicians 
who will use the new assay. This will 
require involvement and education of 
clinicians with results from the clinical 
validation studies. Communication at a 
high level between those implementing 
laboratory monitoring tests and the 
clinicians advising government on the 
use of ARV therapy has been lacking. 
For example, there is no consensus 
regarding the level of monitoring that 
is required. Are ranges of values rather 
than exact values sufﬁ  cient to provide 
inexpensive viral load monitoring? 
Clinician acceptance must play a 
role in devising a testing strategy for 
a given country. Endorsement by an 
international body such as the World 
Health Organization would likely 
increase the acceptability of these assays 
throughout the world.
  Conclusion
    The currently available non-nucleic 
acid-based assays provide better options 
for resource-limited settings in terms 
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of cost and physical requirements. 
However, they require basic laboratory 
infrastructure and as such do not meet 
the need for point-of-care tests for 
patients without access to central or 
district hospitals. Much simpler tests, 
based on dip-stick technology [91] 
or molecular zipper assays [92], are 
in development. It is hoped that data 
describing their applicability will be 
available soon.   
 Acknowledgments
    Other members of the Forum for 
Collaborative HIV Research Alternative Viral 
Load Assay Working Group: Pachamuthu 
Balakrishnan, YRG Care, Chennai, India; 
Bernie Branson, Centers for Disease Control 
and Prevention, Atlanta, Georgia; Deborah 
Burgess, The Bill and Melinda Gates 
Foundation, Seattle, Washington; Isabel 
Cabruja, PerkinElmer Life and Analytical 
Sciences, Turku, Finland; Polly Clayden, 
HIV i-Base, London, United Kingdom; Kate 
Condliffe, Clinton HIV/AIDS Initiative, 
Boston, Massachusetts; Gary Corrigan, 
Cavidi Tech, Uppsala, Sweden; Michel 
de Baar, Primagen, Amsterdam, The 
Netherlands; Robert Downing, Centers for 
Disease Control and Prevention, Entebbe, 
Uganda; Ernest Ekong, Nigeria HIV/AIDS 
Research Network, Lagos, Nigeria, Africa; 
Larry Fox, LabNow, Inc., Austin, Texas; 
Gregg Gonsalves, Gay Men’s Health Crisis, 
New York City, New York; Mauro Guarinieri, 
European AIDS Treatment Group, Bologna, 
Italy; Martine Guillerm, Médecins Sans 
Frontières, Paris, France; Nick Hellmann, 
The Bill and Melinda Gates Foundation, 
Seattle, Washington; Jon Kaplan, Centers 
for Disease Control and Prevention, 
Atlanta, Georgia; Helen Lee, Cambridge 
University, Cambridge, United Kingdom; 
Robert Lloyd, Research Think Tank, Inc, 
Alpharetta, Georgia; Carol Major, Ontario 
HIV Treatment Network, Ontario, Canada; 
Lynn Margherio, Clinton HIV/AIDS 
Initiative, Boston, Massachusetts; Javier 
Martinez-Picardo, Universitat Autonoma 
de Barcelona, Barcelona, Spain; Daniel 
Newman, Centers for Disease Control 
and Prevention, Atlanta, Georgia; Trevor 
Peter, Clinton Foundation, Botswana; Mark 
Rayﬁ  eld, Centers for Disease Control and 
Prevention, Atlanta, Georgia; Renee Ridzon, 
The Bill and Melinda Gates Foundation, 
Seattle, Washington; Tobias Rinke De Wit, 
PharmAccess, Amsterdam, The Netherlands; 
Jeff Safrit, Elizabeth Glaser Pediatrics AIDS 
Foundation, Santa Monica, California; 
Lisa Spacek, Johns Hopkins University, 
Baltimore, Maryland; Tom Spira, Centers 
for Disease Control and Prevention, Atlanta, 
Georgia; Kenji Tamura, World Health 
Organization, Geneva, Switzerland; Michael 
Ussery, National Institutes of Health, 
Bethesda, Maryland; Fred Valentine, New 
York University, New York City, New York; 
Oliviero Varnier, University of Genoa, 
Genoa, Italy; Rainer Ziermann, Bayer 
HealthCare, Berkeley, California. 
    References
    1.  Schuurman R, Descamps D, Weverling GJ, 
Kaye S, Tijnagel J, et al. (1996) Multicenter 
comparison of three commercial methods for 
quantiﬁ  cation of human immunodeﬁ  ciency 
virus type 1 RNA in plasma. J Clin Microbiol 
34: 3016–3022.
    2.  Holguin A, de Mendoza C, Soriano V (1999) 
Comparison of three different commercial 
methods for measuring plasma viraemia in 
patients infected with non-B HIV-1 subtypes. 
Eur J Clin Microbiol Infect Dis 18: 256–259.
    3.  Nolte FS, Boysza J, Thurmond C, Clark WS, 
Lennox JL (1998) Clinical comparison of an 
enhanced-sensitivity branched-DNA assay and 
reverse transcription-PCR for quantitation of 
human immunodeﬁ  ciency virus type 1 RNA in 
plasma. J Clin Microbiol 36: 716–720.
    4.  Nkengasong JN, Kalou M, Maurice C, Bile 
C, Borget MY, et al. (1998) Comparison of 
NucliSens and Amplicor monitor assays for 
quantiﬁ  cation of human immunodeﬁ  ciency 
virus type 1 (HIV-1) RNA in plasma of persons 
with HIV-1 subtype A infection in Abidjan, 
Cote d’Ivoire. J Clin Microbiol 36: 2495–2498.
    5.  Dyer JR, Pilcher CD, Shepard R, Schock J, Eron 
JJ, et al. (1999) Comparison of NucliSens and 
Roche Monitor assays for quantitation of levels 
of human immunodeﬁ  ciency virus type 1 RNA 
in plasma. J Clin Microbiol 37: 447–449.
    6.  Elbeik T, Charlebois E, Nassos P, Kahn J, 
Hecht FM, et al. (2000) Quantitative and 
cost comparison of ultrasensitive human 
immunodeﬁ  ciency virus type 1 RNA viral load 
assays: Bayer bDNA quantiplex versions 3.0 and 
2.0 and Roche PCR Amplicor monitor version 
1.5. J Clin Microbiol 38: 1113–1120.
    7.  Murphy DG, Cote L, Fauvel M, Rene P, 
Vincelette J (2000) Multicenter comparison of 
Roche COBAS AMPLICOR MONITOR version 
1.5, Organon Teknika NucliSens QT with 
Extractor, and Bayer Quantiplex version 3.0 
for quantiﬁ  cation of human immunodeﬁ  ciency 
virus type 1 RNA in plasma. J Clin Microbiol 
38: 4034–4041.
    8.  Elbeik T, Delassandro R, Chen Y-MA, 
Soutchkov SV, Loftus RA, et al. (2003) Global 
cost modeling analysis of HIV-1 and HCV viral 
load assays. Expert Rev Pharmacoeconomics 
Outcomes Res 3: 383–407.
    9.  Crowe S, Turnball S, Oelrichs R, Dunne 
A (2003) Monitoring of HIV infection in 
resource-constrained countries. Clin Infect Dis 
37 (Suppl 1): S25–S35.
    10. Majchrowicz M (2003) Beyond antiretroviral 
access: Low-cost laboratory tests needed for the 
developing world. AIDS 17 (Suppl 4): S12–S15.
    11. Balakrishnan P, Solomon S, Kumarasamy 
N, Mayer KH (2005) Low-cost monitoring 
of HIV infected individuals on highly active 
antiretroviral therapy (HAART) in developing 
countries. Indian J Med Res 121: 245–355. 
    12. Giacomini M, McDermott JL, Giri AA, Martini 
I, Lillo FV, et al. (1998) A novel and improved 
quantitative kinetic software for virologic 
colorimetric assays. J Virol Methods 73: 201–
209.
    13. Schupbach J, Boni J (1993) Quantitative 
and sensitive detection of immune-complex-
dissociated HIV p24 antigen after boiling. J 
Virol Methods 43: 247–256.
    14. Schupbach J, Boni J, Tomasik Z, Jendis J, Seger 
R, et al. (1994) Sensitive detection and early 
prognostic signiﬁ  cance of p24 antigen in heat-
denatured plasma of human immunodeﬁ  ciency 
virus type 1-infected infants. Swiss Neonatal 
HIV Study Group. J Infect Dis 170: 318–324.
    15. Schupbach J, Flepp M, Pontelli D, Tomasik Z, 
Luthy R, et al. (1996) Heat-mediated immune 
complex dissociation and enzyme-linked 
immunosorbent assay signal ampliﬁ  cation 
render p24 antigen detection in plasma as 
sensitive as HIV-1 RNA detection by polymerase 
chain reaction. AIDS 10: 1085–1090.
    16. Boni J, Opravil M, Tomasik Z, Rothen M, 
Bisset L, et al. (1997) Simple monitoring 
of antiretroviral therapy with a signal 
ampliﬁ  cation-boosted HIV-1 p24 antigen assay 
with heat-denatured plasma. AIDS 11: F47–F52.
    17. Ledergerber B, Flepp M, Boni J, Tomosik 
Z, Come RW, et al. (2000) HIV-1 p24 
concentration measured by boosted ELISA of 
heat-denatured plasma correlates with decline 
in CD4 cells, progression to AIDS, and survival: 
Comparison with vira RNA measurement. J 
Infect Dis 181: 1280–1288.
    18. Burgisser P, Vernazza P, Flepp M, Boni J, 
Tomasik Z, et al. (2000) Performance of ﬁ  ve 
different assays for the quantiﬁ  cation of viral 
load in persons infected with various subtypes 
of HIV-1. Swiss HIV Cohort Study. J Acquir 
Immune Deﬁ  c Syndr. 23: 138–144.
    19. Schupbach J, Boni J, Flepp M, Tomasik Z, 
Joller H, et al. (2001) Antiretroviral treatment 
monitoring with an improved HIV-1 p24 
antigen test: An inexpensive alternative to tests 
for viral RNA. J Med Virol 65: 225–232.
    20. Sterling TR, Hoover DR, Astemborski J, Vlahov 
D, Bartlett JA, et al. (2002) Heat-denatured 
HIV-1 protein p24 antigen: Prognostic value in 
adults with early stage disease. J Infect Dis 186: 
1181–1185.
    21. Schupbach J, Boni J, Bisset LR, Tomasik Z, 
Fischer M, et al. (2003) HIV-1 p24 antigen is 
a signiﬁ  cant inverse correlate of CD4 T-cell 
change in patients with suppressed viremia 
under long-term antiretroviral therapy. J 
Acquir Immune Deﬁ  c Syndr 33: 292–299.
    22. Schupbach J, Gunthard H, Joos B, Fischer M, 
Boni J, et al. (2005) HIV-1 p24 may persist 
during long-term highly active antiretroviral 
therapy, increases little during short treatment 
breaks, and its rebound after treatment stop 
correlates with CD4+ T cell loss. J Acquir 
Immune Deﬁ  c Syndr 40: 250–256. 
    23. Pascual A, Cachafeiro A, Funk ML, Fiscus SA 
(2002) Comparison of an assay using signal 
ampliﬁ  cation of the heat-dissociated p24 
antigen with the Roche Monitor HIV RNA 
assay. J Clin Microbiol 40: 2472–2475.
    24. Lombart JP, Vray M, Kafando A, Léeme V, 
Ouedraogo-Taroe R, et al. (2005) Plasma 
virion reverse transcriptase activity and heat 
dissociation-boosted p24 antigen assay for HIV 
load in Burkino Faso, West Africa. AIDS 19: 
1273–1977.
    25. Stevens G, Rekhviashvili N, Scott LE, Gonin 
R, Stevens W (2005) Evaluation of two 
commercially available, inexpensive alternative 
HIV-1 viral load assays for assessing viral load in 
a cohort of HIV-1 infected subtype C patients 
from South Africa. J Clin Microbiol 43: 857–
861.
    26. Ribas SG, Ondoa P, Schupbach J, van der 
Groen G, Fransen K (2003) Performance of a 
quantitative HIV-1 p24 antigen assay on various 
HIV-1 subtypes for the follow-up of HIV-1 
seropositive individuals. J Virol Methods 113: 
29–34.
    27. Prado JG, Shintani A, Boﬁ  ll M, Clotet B, Ruiz 
L, et al. 2004. Lack of longitudinal intrapatient 
correlation between p24 antigenemia and 
levels of HIV-1 RNA in patients with chronic 
HIV infection during structured treatment 
interruptions. J Clin Microbiol 42: 1620–1625.
    28. Bonard D, Rouet F, Toni TA, Minga A, Huet C, 
et al. (2003) Field evaluation of an improved 
assay using a heat-dissociated p24 antigen for 
adults mainly infected with HIV-1 CRF02_AG 
strains in Cote d’Ivoire, West Africa. J Acquir 
Immune Deﬁ  c Syndr 34: 267–273.
    29. Respess RA, Cachafeiro A, Withum D, Fiscus 
SA, Newman D, et al. (2005) Evaluation of an 
October 2006  |  Volume 3  |  Issue 10  |  e417PLoS Medicine  |  www.plosmedicine.org 1749
ultrasensitive p24 antigen assay as a potential 
alternative to HIV-1 RNA viral load in resource-
limited settings. J Clin Microbiol 43: 506–508.
    30. Jennings C, Danilovic A, Burgess D, Morack 
R, Fiscus S, et al. A comparison of two 
non-RNA-based assays for the quantitation 
of HIV [abstract]. 43rd Interscience 
Conference on Antimicrobial Agents and 
Chemotherapy; 2003 September 14–17; 
Chicago, Illinois, United States of America. 
American Society for Microbiology. Available: 
http:⁄⁄gateway.nlm.nih.gov/robot_pages/
MeetingAbstracts/102266490.html. Accessed 7 
September 2006.
    31. Simonds RJ, Brown TM, Thea DM, Orloff 
SL, Steketee RW, et al. (1998) Sensitivity and 
speciﬁ  city of a qualitative RNA detection assay 
to diagnose HIV infection in young infants. 
Perinatal AIDS Collaborative Transmission 
Study. AIDS 12: 1545–1549.
    32. Cunningham CK, Charbonneau TT, Song 
K, Patterson D, Sullivan T, et al. (1999) 
Comparison of human immunodeﬁ  ciency 
virus 1 DNA polymerase chain reaction and 
qualitative and quantitative RNA polymerase 
chain reaction in human immunodeﬁ  ciency 
virus 1-exposed infants. Pediatr Infect Dis J 18: 
30–35.
    33. Young NL, Shaffer N, Chaowanachan T, 
Chotpitayasunondh T, Vanparapar N, et al. 
(2000) Early diagnosis of HIV-1-infected infants 
in Thailand using RNA and DNA PCR assays 
sensitive to non-B subtypes. J Acquir Immune 
Deﬁ  c Syndr 24: 401–407.
    34. Benjamin DK Jr, Miller WC, Fiscus SA, 
Benjamin DK, Morse M, et al. (2001) Rational 
testing of the HIV-exposed infant. Pediatrics 
108: E3.
    35. Lambert JS, Harris DR, Stiehm ER, Moye 
J Jr, Fowler MG, et al. (2003) Performance 
characteristics of HIV-1 culture and HIV-1 
DNA and RNA ampliﬁ  cation assays for early 
diagnosis of perinatal HIV-1 infection. J Acquir 
Immune Deﬁ  c Syndr 34: 512–519.
    36. World Health Organization (2004) Scaling 
up antiretroviral therapy in resource-limited 
settings: Treatment guidelines for a public 
health approach. 2003 revision. Available: 
http:⁄⁄www.who.int/3by5/publications/
documents/arv_guidelines/en/. Accessed 6 
September 2006.
    37. Lyamuya E, Bredberg-Raden U, Massawe A, 
Urassa E, Kawo G, et al. (1996) Performance 
of a modiﬁ  ed HIV-1 p24 antigen assay for early 
diagnosis of HIV-1 infection in infants and 
prediction of mother-to-infant transmission 
of HIV-1 in Dar es Salaam, Tanzania. J Acquir 
Immune Deﬁ  c Syndr 12: 421–426.
    38. Nadal D, Boni J, Kind C, Varinier OE, 
Steiner F, et al. (1999) Prospective evaluation 
of ampliﬁ  cation-boosted ELISA for heat-
denatured p24 antigen for diagnosis and 
monitoring of pediatric HIV-1 infections. J 
Infect Dis 180: 1089–1095.
    39. Sutthent R, Gaudart N, Chokpaibulkit K, 
Tanliang N, Kanoksinsombath C, et al. (2003) 
p24 antigen detection assay modiﬁ  ed with a 
booster step for diagnosis and monitoring of 
HIV-1 infection. J Clin Microbiol 41: 1016–
1022.
    40. Sherman GG, Stevens G, Stevens W (2004) 
Affordable diagnosis of HIV infection in infants 
by p24 antigen detection. Pediatr Infect Dis J 
23: 173–176.
    41. Zijenah LS, Tobaiwa O, Rusakaniko S, Nathoo 
KJ, Nhembe M, et al. (2005) Signal-boosted 
qualitative ultrasensitiev p24 antigen assay 
for diagnosis of subtype C HIV-1 infection 
in infants under the age of 2 years. J Acquir 
Immune Deﬁ  c Syndr 39: 391–394.
    42. De Baets AJ, Edidi BS, Kasali MJ, Beelaert G, 
Schrooten W, et al. (2005) Pediatric human 
immunodeﬁ  ciency virus screening in an 
African district hospital. Clin Diagn Lab 
Immunol 12: 86–92.
    43. Knuchel MC, Tomasik Z, Speck RF, Luthy R, 
Schupbach J (2006) Ultrasensitive quantitative 
HIV-1 p24 antigen assay adapted to dried 
plasma spots to improve treatment monitoring 
in low-resource settings. J Clin Virol 36: 64–67.
    44. Li CC, Seidel KD, Coombs RW, Frenkel LM 
(2005) Detection and quantiﬁ  cation of HIV-1 
p24 antigen in dried whole blood and plasma 
on ﬁ  lter paper stored under various conditions. 
J Clin Microbiol 43: 3901–3905.
    45. Patton JC, Sherman GG, Coovadia AH, Stevens 
WS, Meyers TM (2006) Ultrasensitive HIV-1 
p24 antigen assay modiﬁ  ed for use on dried 
whole blood spots as a reliable, affordable test 
for infant diagnosis. Clin Vaccine Immunol 13: 
152–155. 
    46. Malmsten A, Shao XW, Aperia K, Corrigan 
GE, Sandstrom E, et al. (2003) HIV-1 viral load 
determination based on reverse transcriptase 
activity recovered from human plasma. J Med 
Virol 71: 347–359.
    47. Malmsten A, Shao XW, Sjodahl S, Fredriksson 
EL, Pettersson I, et al. (2005) Improved HIV-
1 viral load determination based on reverse 
transcriptase activity recovered from human 
plasma. J Med Virol 76: 291–296.
    48. Braun J, Plantier JC, Hellot MF, Tuaillon E, 
Gueudin M, et al. (2003) A new quantitative 
HIV load assay based on plasma virion reverse 
transcriptase activity for the different types, 
groups and subtypes. AIDS 17: 331–336.
    49. Greengrass VL, Turnbull SP, Hocking J, Dunne 
AL, Tachedjian G, et al. (2005) Evaluation of a 
low cost reverse transcription assay for plasma 
HIV-1 viral load monitoring. Curr HIV Res 3: 
183–190.
    50. Seyoum E, Wolday D, Girma M, Malmsten A, 
Meselle T, et al. (2006) Reverse transcriptase 
activity for quantitation of HIV-1 subtype C in 
plasma: Relation to RNA copy number and 
CD4 T-cell count. J Med Virol 78: 161-168.
    51. Sivapalasingam S, Essajee S, Nyambi PN, 
Itri V, Hanna B, et al. (2005) Human 
immunodeﬁ  ciency virus (HIV) reverse 
transcriptase activity correlates with HIV RNA 
load: Implications for resource-limited settings. 
J Clin Microbiol 43: 3793–3796.
    52. Lewin SR, Vesanen M, Kostrikos L, Hurley 
A, Duran M, et al. (1999) Use of real-time 
PCR and molecular beacons to detect virus 
replication in HIV-1 infected individuals on 
prolonged effective antiretroviral therapy. J 
Virol 73: 6099–6103.
    53. de Baar MP, Timmermans EC, Bakker M, 
de Rooij E, van Gemen B, et al. (2001) One-
tube real-time isothermal ampliﬁ  cation 
assay to identify and distinguish human 
immunodeﬁ  ciency virus type 1 subtypes A, B, 
and C and circulating recombinant forms AE 
and AG. J Clin Microbiol 39: 1895–1902.
    54. de Baar MP, Timmermans EC, Buitelaar M, 
Westrop M, Dekker JT, et al. (2003) Evaluation 
of the HIV-1 RNA RetinaTM Rainbow assay 
on plasma and dried plasma spots: Correlation 
with the Roche Amplicor HIV-1 Monitor v 1.5 
assay. Antivir Ther 8 (Suppl 1): S533. 
    55. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, 
Mican JM, et al. (2003) New real-time reverse 
transcriptase-initiated PCR assay with single-
copy sensitivity for human immunodeﬁ  ciency 
virus type 1 RNA in plasma. J Clin Microbiol 
41: 4531–4536.
    56. Ayele W, Pollakis G, Abebe A, Fisseha B, 
Tegbaru B, et al. (2004) Development of a 
nucleic acid sequence-based ampliﬁ  cation 
assay that uses gag-based molecular beacons to 
distinguish between human immunodeﬁ  ciency 
virus type 1 subtype C and C’ infections in 
Ethiopia. J Clin Microbiol 42: 1534–1541.
    57. Luo W, Yang H, Rathbun K, Pau CP, Ou CY 
(2005) Detection of HIV-1 DNA in dried blood 
spots by a duplex real-time PCR assay. J Clin 
Microbiol 43: 1851–1857.
    58. Stevens W, Wiggill T, Horsﬁ  eld P, Coetzee L, 
Scott LE (2005) Evaluation of the NucliSens 
EasyQ assay in HIV-1 infected individuals in 
South Africa. J Virol Methods 124: 105–110.
    59. Yao J, Liu Z, Ko LS, Pan G, Jiang Y (2005) 
Quantitative detection of HIV-1 RNA using 
NucliSens EasyQ HIV-1 assay. J Virol Methods 
129: 40–46. .
    60. Rekhviashvii N, Stevens G, Scott L, Stevens 
W (2006) Fluorogenic LUX primer for 
quantitation of HIV-1 by real-time RT-PCR. Mol 
Biotechnol 32: 101–110.
    61. Swanson P, Huang S, Holzmayer V, Bodelle P, 
Yamaguchi J, et al. (2006) Performance of the 
automated Abbott RealTime HIV-1 assay on 
a genetically diverse panel of specimens from 
Brazil. J Virol Methods 134: 237–243.
    62. Rouet F, Ekouevi DK, Chaix ML, Burgard 
N, Inwoley A, et al. (2005) Transfer and 
evaluation of an automated, low-cost real-time 
reverse transcription-PCR test for diagnosis 
and monitoring of HIV-1 infection in a 
West African resource-limited setting. J Clin 
Microbiol 43: 2709–2717.
    63. Gueudin M, Simon F (2005) Plasma RNA viral 
load in HIV-1 group O infection by real-time 
PCR. Methods Mol Biol 304: 221–228. 
    64. Gueudin M, Plantier JC, Damond F, Roques 
P, Mauclere P, et al. (2003) Plasma viral RNA 
assay in HIV-1 group O infection by real-time 
PCR. J Virol Methods 113: 43–49.
    65. Candotti D, Temple J, Owusu-Ofori S, Allain JP 
(2004) Multiplex real-time quantitative realtime 
PCR assay for hepatitis B virus, hepatitis C virus, 
and human immunodeﬁ  ciency virus type 1. J 
Virol Methods 118: 39–47. 
    66. Cassol S, Gill MJ, Pilon R, Cormier M, Voigt 
RF, et al. (1997) Quantiﬁ  cation of human 
immunodeﬁ  ciency virus type 1 RNA from dried 
plasma spots collected on ﬁ  lter paper. J Clin 
Microbiol 35: 2795–2801.
    67. Fiscus SA, Brambilla D, Grosso L, Schock J, 
Cronin M (1998) Quantitation of human 
immunodeﬁ  ciency virus type 1 RNA in plasma 
by using blood dried on ﬁ  lter paper. J Clin 
Microbiol 36: 258–260.
    68. O’Shea S, Mullen J, Corbett K, Chrystie I, 
Newell ML, et al. (1999) Use of dried whole 
blood spots for quantiﬁ  cation of HIV-1 RNA. 
AIDS 13: 630–631.
    69. Biggar RJ, Broadhead R, Janes M, Kumwenda 
N, Taha TE, et al. (2001) Viral levels in 
newborn African infants undergoing primary 
HIV-1 infection. AIDS 15: 1311–1313.
    70. Brambilla D, Jennings C, Aldrovandi G, Bremer 
J, Comeau AM, et al. (2003) Multicenter 
evaluation of use of dried blood and plasma 
spot specimens in quantitative assays for human 
immunodeﬁ  ciency virus RNA: measurement, 
precision, and RNA stability. J Clin Microbiol 
41: 1888–1893.
    71. Mwaba P, Cassol S, Nunn A, Pilon R, Chintu 
C, et al. (2003) Whole blood versus plasma 
spots for measurement of HIV-1 viral load in 
HIV-infected African patients. Lancet 362: 
2067–2068.
    72. Uttayamakul S, Likanonsakul S, 
Sunthornkachit R, Kuntiranont K, 
Luoisirirotchankul S, et al. (2005) Usage of 
dried blood spots for molecular diagnosis and 
monitoring HIV-1 infection. J Virol Methods 
128: 128–134.
    73. Rollins NC, Dedicoat M, Danaviah S, Page T, 
Bishop K, et al. (2002) Prevalence, incidence, 
and mother-to-child transmission of HIV-1 in 
rural South Africa. Lancet 360: 389.
    74. Cassol S, Salas T, Arella M, Neumann P, 
Schechter MT, et al. (1991) Use of dried 
blood spot specimens in the detection of 
human immunodeﬁ  ciency virus type 1 by the 
polymerase chain reaction. J Clin Microbiol. 
29: 667–671.
    75. Cassol SA, Lapointe N, Salas T, Hankins C, 
Arella M, et al. (1992) Diagnosis of vertical 
HIV-1 transmission using the polymerase chain 
reaction and dried blood spot specimens. J 
Acquir Immune Deﬁ  c Syndr 5: 113–119.
October 2006  |  Volume 3  |  Issue 10  |  e417PLoS Medicine  |  www.plosmedicine.org 1750
    76. Comeau AM, Harris J, McIntosh K, Weiblen 
BJ, Hoff R, et al. (1992) Polymerase chain 
reaction in detecting HIV-1 infection among 
seropositive infants: Relation to clinical status 
and age and to results of other assays. J Acquir 
Immune Deﬁ  c Syndr 5: 271–278.
    77. Cassol S, Butcher A, Kinard S, Spadoro J, 
Sy T, et al. (1994) Rapid screening for early 
detection of mother-to-child transmission of 
human immunodeﬁ  ciency virus type 1. J Clin 
Microbiol 32: 2641–2645.
    78. Yourno J, Conroy J (1992) A novel polymerase 
chain reaction method for detection of human 
immunodeﬁ  ciency virus in dried blood spots 
on ﬁ  lter paper. J Clin Microbiol 30: 2887–2892.
    79. Comeau AM, Hsu HW, Schwerzler M, 
Mushinsky G, Walter E, et al. (1993) Identifying 
human immunodeﬁ  ciency virus infection at 
birth: Application of polymerase chain reaction 
to Guthrie cards. J Pediatr 123: 252–258.
    80. Nyambi PN, Fransen K, De Beenhouwer H, 
Chomba EN, Temmerman M, et al. (1994) 
Detection of human immunodeﬁ  ciency virus 
type 1 (HIV-1) in heel prick blood on ﬁ  lter 
paper from children born to HIV-1-seropositive 
mothers. J Clin Microbiol 32: 2858–2860.
    81. Biggar RJ, Miley W, Miotti P, Taha TE, Butcher 
A, et al. (1997) Blood collection on ﬁ  lter paper: 
A practical approach to sample collection for 
studies of perinatal HIV transmission. J Acquir 
Immune Deﬁ  c Syndr 14: 368–373.
    82. Panteleeff DD, John G, Nduati R, Mbori-
Ngacha D, Richardson B, et al. (1999) Rapid 
method for screening dried blood samples on 
ﬁ  lter paper for human immunodeﬁ  ciency virus 
type 1 DNA. J Clin Microbiol 37: 350–353.
    83. Beck IA, Drennan KD, Melvin AJ, Mohan KM, 
Herz AM, et al. (2001) Simple, sensitive, and 
speciﬁ  c detection of human immunodeﬁ  ciency 
virus type 1 subtype B DNA in dried blood 
samples for diagnosis in infants in the ﬁ  eld. J 
Clin Microbiol 39: 29–33.
    84. Fischer A, Lejczak C, Lambert C, Servais 
J, Makombe N, et al. (2004) Simple DNA 
extraction method for dried blood spots and 
comparison of two PCR assays for diagnosis of 
vertical human immunodeﬁ  ciency virus type 1 
transmission in Rwanda. J Clin Microbiol 42: 
16–20.
    85. Sherman GG, Stevens G, Jones SA, Horsﬁ  eld P, 
Stevens WS (2005) Dried blood spots improve 
access to HIV diagnosis and care for infants in 
low-resource settings. J Acquir Immune Deﬁ  c 
Syndr 38: 615–617.
    86. Sriwanthana B, Wetprasit N, Chareonsook S, 
Janejai N, Chareonsiriwatana W (2003) A study 
to implement early diagnosis of HIV infection 
in infants born to infected mothers. Southeast 
Asian J Trop Med Public Health 34 (Suppl 3): 
221–226. 
    87. Li CC, Beck IA, Seidel KD, Frenkel LM (2004) 
Persistence of human immunodeﬁ  ciency virus 
type 1 subtype B DNA in dried-blood samples 
on FTA ﬁ  lter paper. J Clin Microbiol 42: 3847–
3849.
    88. Behets F, Kashamuka M, Pappaioanou M, 
Green TA, Ryder RW, et al. (1992) Stability 
of human immunodeﬁ  ciency virus type 1 
antibodies in whole blood dried on ﬁ  lter paper 
and stored under various tropical conditions 
in Kinshasa, Zaire. J Clin Microbiol 30: 1179–
1182.
    89. Cassol S, Weniger BG, Babu PG, Salminen 
MO, Zheng X, et al. (1996) Detection of HIV 
type 1 env subtypes A, B, C, and E in Asia using 
dried blood spots: A new surveillance tool 
for molecular epidemiology. AIDS Res Hum 
Retroviruses 12: 1435–1441.
    90. Lee DH, Li L, Andrus L, Prince AM (2002) 
Stabilized viral nucleic acids in plasma as 
an alternative shipping method for NAT. 
Transfusion 42: 409–413.
    91. Dineva MA, Candotti D, Fletcher-Brown F, 
Allain JP, Lee H (2005) Simultaneous visual 
detection of multiple viral amplicons by 
dipstick assay. J Clin Microbiol 43: 4015–4021.
    92. Guttikonda S, Wang W, Suresh M 
(2004) Molecular zipper assays: A simple 
homosandwich with the sensitivity of PCR. J 
Pharm Pharm Sci 7: 7–16.  
October 2006  |  Volume 3  |  Issue 10  |  e417